摘要
用LAK细胞与白细胞介素2(γIL-2)及胸腺因子D(TFD)混合,于术中、术后注入瘤周和瘤腔,治疗7例脑胶质瘤患者,未见明显的毒性反应。1例CT显示术中残留的肿瘤消失;1例治疗部位未见肿瘤复发,而对照部位复发。该疗法用于临床是安全和具有一定疗效的。
Autologous or heterologous lymphokine-activated killer (LAK) cells initiated by recombinant inter- leukin-2 (rIL-2) and thymic factor D(TFD) were suspended in saline, rIL-2 and TFD, then were direct- ly injected into the brain tissue surrounding the tumor cavity left following tumor removal during cran- iotomy and infused into intracavity after the operation. Seven patients with glioma were treated. There have been no signs of systemic or neurotoxicity following treatment. The residue disappeared on comput- ed tomographic scan. Another showed no tumor recurrence at the site of treatment,but the controlled site did. We discussed the predominance and feasibility as well as the prevention and treatment of the side effects of intralesional infusion of LAK cells plus rIL-2 and TFD. The results demonstrated that the im- munotherapeutic regimen we have described is safe,feasible and effective for the treatment of patients with glioma.
关键词
脑肿瘤
杀伤细胞
免疫疗法
IL-2
cerebral tumor
immunotherapy
LAK
interleukin--2
thymic factor D
